First half trading significantly stronger
In a statement to accompany yesterday's AGM, Eco Animal Health reports that trading in the first half of FY26 “has been significantly stronger compared to the same period last year” despite “currency headwinds and tariff challenges”. Revenue is seen over 15% ahead year-on-year (H1 2025: £33.2m), i.e. indicative of c.£38m, with particular strength seen in the China/Japan segment (over 40%YoY growth) and North America (over 25% YoY growth). The Group also expects to report improved gross margins for the period, resulting in a “material increase in adjusted EBITDA” compared to H1 25 (£0.45m).Whilst EAH’s enteric and respiratory antibiotic Aivlosin® remains the driver of performance, the cash it generates continues to fuel the Group programme for development of novel next-generation treatments. Following recent regulatory filings in Europe for the first of products in the pipeline, mycoplasma poultry vaccine ECOVAXXIN® MS, we expect further submissions in the coming 12 months, with up to 9 products expected to receive US and EU approval in the next 5-6 years.
In our view, Eco Animal Health’s valuation continues to underplay the well-funded investment in its new product range and their future value: our Fair Value is 136p/share.
Eco Animal Health Group is engaged in the manufacture and supply of animal health products. Co.'s activities were conducted through a network including both regional offices, (notably in Shanghai and Princeton) and overseas subsidiaries. Co.'s patented molecule, Aivlosin® is used for the treatment of pigs and poultry diseases and is prescribed under veterinary control for the short duration treatment of diagnosed diseases. Co.'s products also include Ecomectin, an endectocide that controls worms, ticks, lice and mange in grazing stock and pigs.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.